News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Reminder - Atrix Laboratories, Inc. (ATRX) Schedules Third Quarter Conference Call For November 9, 2004, 11:00 A.M. EST

10/19/2005 5:12:09 PM

FORT COLLINS, Colo., Nov. 9 /PRNewswire-FirstCall/ -- Atrix Laboratories, Inc. announced today that it has scheduled the release of third quarter consolidated financial results on November 9, 2004. In conjunction with the release, Atrix management will host a conference call on November 9, 2004 at 11:00 a.m., EST. The conference will be available by telephone at 800-540-0559 with the ID: ATRIX. A replay of the call will be available for one week after the event at 888-567-0671. The conference call will also be simultaneously webcast over the Internet. The link for the webcast can be found at Atrix's homepage at


Atrix Laboratories, Inc. is an emerging specialty pharmaceutical company focused on advanced drug delivery. With unique sustained release and topical technologies, Atrix is currently developing a diverse portfolio of proprietary products, including oncology, and dermatology products. The company also partners with large pharmaceutical and biotechnology companies to apply its proprietary technologies to new chemical entities or to extend the patent life of existing products. Additional information is available on the Atrix Laboratories, Inc. website at

Statements made in company press releases and conference calls, which are not historical facts, are forward-looking statements, as the term is defined under the Private Securities Litigation Reform Act of 1995. Such forward-looking statements are subject to certain risks and uncertainties which can cause actual results to differ materially from those currently anticipated, due to a number of factors which include, but are not limited to, risks associated with product demand, pricing, market acceptance of current and proposed products, changing economic conditions, risks in product and technology development and competition from other products and treatments. For additional information about risk factors, please see the reports filed by the company with the SEC, including the company's Annual Report on Form 10-K for the year ended December 31, 2003 and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2004. All forward-looking statements in this press release are made as of the date hereof, based on information available to the company as of the date hereof, and the company assumes no obligation to update or revise any of its forward-looking statements even if experience or future changes show that the indicated results or events will not be realized.

Atrix Laboratories, Inc.

CONTACT: Jennifer Geraci, Investor Relations Representative of AtrixLaboratories, Inc., +1-970-482-5868

Read at

comments powered by Disqus